Bank of America’s Galectin Therapeutics GALT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$268K Buy
57,715
+3,853
+7% +$9.99K ﹤0.01% 5245
2026
Q1
$150K Buy
53,862
+28,799
+115% +$87.6K ﹤0.01% 5446
2025
Q4
$104K Sell
25,063
-264
-1% -$1.39K ﹤0.01% 5610
2025
Q3
$107K Buy
25,327
+14,285
+129% +$53.7K ﹤0.01% 6568
2025
Q2
$23.3K Sell
11,042
-3,766
-25% -$5.63K ﹤0.01% 7025
2025
Q1
$18.1K Sell
14,808
-23,550
-61% -$33K ﹤0.01% 6995
2024
Q4
$49.5K Buy
38,358
+19,316
+101% +$46.3K ﹤0.01% 6641
2024
Q3
$52.4K Buy
19,042
+686
+4% +$1.69K ﹤0.01% 6527
2024
Q2
$41.5K Buy
18,356
+3,623
+25% +$11K ﹤0.01% 6562
2024
Q1
$35.2K Buy
14,733
+9,101
+162% +$17.2K ﹤0.01% 6611
2023
Q4
$9.35K Buy
5,632
+27
+0.5% +$52 ﹤0.01% 6916
2023
Q3
$10.8K Hold
5,605
﹤0.01% 6844
2023
Q2
$8.07K Hold
5,605
﹤0.01% 6909
2023
Q1
$11.8K Sell
5,605
-340
-6% -$549 ﹤0.01% 6886
2022
Q4
$6.72K Sell
5,945
-2
-0% -$3 ﹤0.01% 7006
2022
Q3
$10K Sell
5,947
-1,850
-24% -$3.46K ﹤0.01% 7234
2022
Q2
$10K Sell
7,797
-1,800
-19% -$2.59K ﹤0.01% 7386
2022
Q1
$15K Buy
9,597
+3,044
+46% +$5.89K ﹤0.01% 7620
2021
Q4
$14K Buy
6,553
+1,036
+19% +$2.96K ﹤0.01% 7620
2021
Q3
$21K Sell
5,517
-6,700
-55% -$22.7K ﹤0.01% 7370
2021
Q2
$40K Sell
12,217
-35,406
-74% -$126K ﹤0.01% 6923
2021
Q1
$103K Buy
47,623
+36,832
+341% +$82.5K ﹤0.01% 6373
2020
Q4
$24K Buy
10,791
+3,265
+43% +$8.57K ﹤0.01% 6547
2020
Q3
$20K Sell
7,526
-3,369
-31% -$9.43K ﹤0.01% 6281
2020
Q2
$33K Buy
10,895
+6,462
+146% +$16.3K ﹤0.01% 6134
2020
Q1
$9K Sell
4,433
-5,309
-54% -$12.9K ﹤0.01% 6385
2019
Q4
$27K Sell
9,742
-1,334
-12% -$4.63K ﹤0.01% 6435
2019
Q3
$40K Buy
11,076
+266
+2% +$961 ﹤0.01% 6388
2019
Q2
$44K Sell
10,810
-11,219
-51% -$48.6K ﹤0.01% 6352
2019
Q1
$112K Buy
22,029
+17,629
+401% +$84.6K ﹤0.01% 5823
2018
Q4
$15K Sell
4,400
-1,975
-31% -$9.43K ﹤0.01% 6551
2018
Q3
$38K Buy
6,375
+3,375
+113% +$18.6K ﹤0.01% 6320
2018
Q2
$19K Sell
3,000
-5,260
-64% -$25.6K ﹤0.01% 6522
2018
Q1
$39K Buy
8,260
+1,010
+14% +$4.71K ﹤0.01% 6137
2017
Q4
$24K Sell
7,250
-353
-5% -$892 ﹤0.01% 6360
2017
Q3
$16K Buy
7,603
+1,853
+32% +$3.67K ﹤0.01% 6362
2017
Q2
$14K Sell
5,750
-78
-1% -$208 ﹤0.01% 6331
2017
Q1
$13K Sell
5,828
-3,480
-37% -$5.25K ﹤0.01% 6460
2016
Q4
$9K Sell
9,308
-2
-0% -$2 ﹤0.01% 6582
2016
Q3
$10K Sell
9,310
-449
-5% -$798 ﹤0.01% 6386
2016
Q2
$15K Sell
9,759
-418
-4% -$613 ﹤0.01% 6354
2016
Q1
$15K Hold
10,177
﹤0.01% 6245
2015
Q4
$17K Sell
10,177
-6,640
-39% -$15.2K ﹤0.01% 6476
2015
Q3
$39K Sell
16,817
-798
-5% -$1.88K ﹤0.01% 6043
2015
Q2
$48K Sell
17,615
-81
-0.5% -$244 ﹤0.01% 5953
2015
Q1
$60K Buy
17,696
+6,979
+65% +$24.9K ﹤0.01% 5574
2014
Q4
$37K Sell
10,717
-5,904
-36% -$26.1K ﹤0.01% 6503
2014
Q3
$84K Buy
16,621
+11,254
+210% +$87.6K ﹤0.01% 6142
2014
Q2
$75K Sell
5,367
-1,700
-24% -$21.2K ﹤0.01% 6350
2014
Q1
$108K Buy
7,067
+5,022
+246% +$71.5K ﹤0.01% 5934
2013
Q4
$16K Buy
+2,045
New +$18.9K ﹤0.01% 7113
2013
Q3
Sell
-44
Closed 7926
2013
Q2
$0 Buy
+44
New +$180 ﹤0.01% 7707

Other funds holding GALT

Bank of America's GALT Position: Q2 2026 in Review

Bank of America increased its Galectin Therapeutics (GALT) stake by 7.2% in Q2 2026, buying an estimated $9.99K and bringing the position to 57,715 shares worth $268K. The position accounts for ﹤0.01% of the portfolio, ranked #5245.

Bank of America first reported a position in GALT in Q2 2013 and has held it in 52 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Bank of America held 57,715 shares of Galectin Therapeutics worth $268K as of Q2 2026.
  • Bank of America bought 3,853 Galectin Therapeutics shares in Q2 2026, an estimated $9.99K.
  • Galectin Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #5245 holding.
  • Bank of America first reported a position in Galectin Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.